177 related articles for article (PubMed ID: 33135335)
21. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis.
Guller U; Tarantino I; Cerny T; Ulrich A; Schmied BM; Warschkow R
Gastric Cancer; 2017 Jan; 20(1):49-60. PubMed ID: 26649434
[TBL] [Abstract][Full Text] [Related]
22. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
[No Abstract] [Full Text] [Related]
23. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
[TBL] [Abstract][Full Text] [Related]
24. Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study.
Zhao F; Yu X; Xu M; Ye S; Zang S; Zhong W; Ren G; Chen X; Yan S
Front Oncol; 2019; 9():1467. PubMed ID: 31998638
[No Abstract] [Full Text] [Related]
25. Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study.
Orrason AW; Garmo H; Styrke J; Dickman PW; Stattin P
Am J Epidemiol; 2021 Oct; 190(10):2053-2063. PubMed ID: 34007984
[TBL] [Abstract][Full Text] [Related]
26. Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer.
Zhou Y; Zhang R; Ding Y; Wang Z; Yang C; Tao S; Liang C
Cancer Med; 2020 Apr; 9(8):2710-2722. PubMed ID: 32087609
[TBL] [Abstract][Full Text] [Related]
27. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
28. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
[TBL] [Abstract][Full Text] [Related]
29. The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer.
Tilki D; Würnschimmel C; Preisser F; Graefen M; Huland H; Mandel P; Tennstedt P
Eur Urol Focus; 2020 Mar; 6(2):255-258. PubMed ID: 32033909
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China.
Liu D; Kuai Y; Zhu R; Zhou C; Tao Y; Han W; Chen Q
Sci Rep; 2020 Jun; 10(1):9104. PubMed ID: 32499554
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy analysis of radiotherapy combined with surgery for locally advanced rectal mucinous adenocarcinoma: a retrospective study based on data of Surveillance, Epidemiology, and End results population].
Zhang Y; Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):85-93. PubMed ID: 30703799
[TBL] [Abstract][Full Text] [Related]
32. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
33. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
[TBL] [Abstract][Full Text] [Related]
34. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.
Sabolch A; Feng FY; Daignault-Newton S; Halverson S; Blas K; Phelps L; Olson KB; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e351-60. PubMed ID: 21493015
[TBL] [Abstract][Full Text] [Related]
35. Competing risk of the specific mortality among Asian-American patients with prostate cancer: a surveillance, epidemiology, and end results analysis.
Wu D; Yang Y; Jiang M; Yao R
BMC Urol; 2022 Mar; 22(1):42. PubMed ID: 35331219
[TBL] [Abstract][Full Text] [Related]
36. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
37. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
38. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
39. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
[TBL] [Abstract][Full Text] [Related]
40. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
